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Abstract
Tuberculosis (TB) continues to be a major health hazard worldwide due to 
the resurgence of drug discovery strains of Mycobacterium tuberculosis (Mtb) and 
co-infection. For decades drug discovery has concentrated on identifying ligands 
for ~10 Mtb targets, hence most of the identified essential proteins are not utilised 
in TB chemotherapy. Here computational techniques were used to identify ligands 
for the orphan Mtb proteins. These range from ligand-based and structure-based 
virtual screening modelling the proteome of the bacterium. Identification of 
ligands for most of the Mtb proteins will provide novel TB drugs and targets and 
hence address drug resistance, toxicity and the duration of TB treatment.
Keywords: Mycobacterium tuberculosis, target deorphaning, target deconvolution, 
proteome modelling, virtual screening
1. Introduction
Tuberculosis (TB) continues to be a major public health concern with over 2 
billion people currently infected, 8.6 million new cases per year, and more than 
1.3 million deaths annually [1]. The current drug-regimen combination for drug 
sensitive TB consists of isoniazid, rifampicin, ethambutol and pyrazinamide, 
administered over 6 months [2]. If this treatment fails, second-line drugs are used, 
such as para-aminosalicylate (PAS) and fluoroquinolones, which are usually either 
less effective or more toxic with serious side effects. Although this regimen has a 
high success rate, it is marred by compliance issues, which have resulted in the rise 
of multidrug resistant (MDR), extensively drug resistant (XDR) and totally drug 
resistant (TDR) strains of the causative agent, Mycobacterium tuberculosis (Mtb) 
[3, 4], in both immunocompetent and immunocompromised patients worldwide 
[5]. However, it took about 40 years for a new TB drug to be discovered and most 
of the current TB drugs target a total of only ~10 proteins, even though the com-
plete genome of Mtb was published nearly 20 years ago [6]. Consequently, most 
of the essential proteins are orphans since their ligands are still to be identified. In 
our context, target deorphaning or deconvolution encompasses identification of 
ligands for Mtb proteins not currently exploited in TB chemotherapy and those of 
old TB targets. Targeting further essential proteins should allow the fight against 
drug resistance to be enhanced, and possibly lead to a reduction in the duration of 
TB treatment.
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6.2 Comparative 3D modelling of proteins
Comparative modelling proteins, based on the fold recognition and structural 
alignment with the closest homologues that have experimentally solved structures, 
began using interactive graphics in the 1970s [41–43]. The development of auto-
mated modelling software began in the 1980s, initially with Composer [44] and 
later developed with Comparer [45] and Modeller [46], based on satisfaction of 3D 
restraints derived from structurally aligned homologues. Modeller has now been 
cited ~10,500 times in the literature!
6.2.1 Computational modelling pipelines and structural proteome databases
Rapid progress in this and other related software coupled with increasing com-
puting power has enabled genome scale prediction of protein structures, as a viable 
alternative to experimental determination. In order to construct computational models 
of all gene products, which we here refer to as the structural proteome, we identify 
templates by a sequence-structure homology search using Fugue [47], which uses 
local-structural-environment-specific substitution tables to predict the likelihood of a 
common 3D structure. We have incorporated Fugue into a pipeline (Vivace), in which 
templates are selected from TOCCATA (Ochoa Montaño and Blundell, unpublished), 
a database of consensus profiles built from CATH 3.5 [48] and SCOP 1.75A [49] based 
classification of proteins structures (PDB files). PDBs within each profile are clustered 
based on sequence similarity using CD-HIT [50] and structures are aligned using 
BATON, a modified version of COMPARER [45]. After further optimization of the 
clusters by discarding templates with more than 20% difference in sequence identity to 
the maximum hit, remaining templates are classified into states based on ligand binding 
and oligomerization. Five different states, known as “liganded-monomeric,” “liganded-
complexed,” “apo-monomeric,” “apo-complexed” and “any,” are generated in each 
profile hit. Models are built in each of these states using Modeller 9.10 [46] and refined. 
Later NDOPE, GA341 [51] Molprobity [52] and SSAG [53] are used to determine the 
quality of the models.
6.2.2 Mycobacterial proteome databases
The first application of this approach was to construct the Chopin Database  
(http://mordred.bioc.cam.ac.uk/chopin/about), a database of protein structures for 
H37Rv strain of Mtb. This has provided structures that are reasonably certain for around 
65% of gene products. These have proved reliable indicators of the overall structures but 
may have some uncertainties especially in loop regions and domain-domain relation-
ships. A further ~19% probably have correct folds while the remaining would unlikely 
to be correct. Nevertheless, compared to those structures defined experimentally by 
X-ray analysis, this represents a 6-fold increase of structural information available that 
might be useful in assessing druggability and the impacts of mutations.
Similar models of the structural proteome for M. abscessus (Skwark et al., 
unpublished) and M. leprae (Vedithi et al., unpublished) have been developed in 
the group. In M. leprae, of the 1615 gene products, templates were identified for 
1429 gene products and we were able to model 1161 proteins with high confidence. 
A total of 36,408 models were built in different ligand bound and oligomeric states 
for the 1161 proteins. The distribution of Fugue Z score across models indicates 
that only 4% of the proteome has no hits and 15% has poor scores. ~80% of the 
proteome has acceptable and good hits, and the corresponding Z scores. Around 
47% of the protein queries identified templates with identity and coverage greater 
than 40 and 67% of the models in the proteome are of best quality as estimated by 
NDOPE, GA341, Molprobity and Secondary Structure Agreement (SSAG).
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6.2.3 Oligomeric protein models
Current work on structural proteomes includes efforts to extend the modelling 
pipeline to homo-oligomeric (and eventually hetero-oligomeric) structures using com-
parative approaches (Malhotra et al., unpublished), extending models and improving 
models of small molecule complexes, and linking individual protein structures into 
the metabolic networks and interactions in the cell (Bannerman et al., unpublished). 
An example of an oligomeric structure is CTP-synthase, encoded by PyrG, which is 
an essential gene in Mtb identified by transposon saturation mutagenesis [54] and 
catalyses ATP-dependent amination of UTP to CTP with either L-glutamine or ammo-
nia. The allosteric effector GTP functions by stabilising the protein conformation that 
binds to the tetrahedral intermediates formed during glutamine hydrolysis. Its closest 
homologue in M. leprae ML1363 is a target of choice and was modelled using Vivace 
during the proteome modelling exercise. We modelled the apomeric and ligand bound 
states of the model and oligomerized the protomer using our inhouse oligomerization 
pipeline. The protomeric and oligomeric states are depicted in Figure 3A and B.
The models were built by using templates PDB-IDs: 4zdI and 4zdK for PyrG 
of Mtb [55]. Both the templates are 89% identical and 100% coverage to the query 
sequence. The superposition of the models with the templates indicated a root mean 
square deviation (RMSD) of 0.758.
6.3 Structural implications of mutations
We have also spent time over 2 decades analysing the impacts of mutations 
evident in the increasing wealth of available genome sequences for pathogenic myco-
bacteria and cancers. We originally developed SDM [56] in 1997, a method depend-
ing on statistical analysis of environment-dependent amino-acid substitution tables 
[57, 58]. In 2013 machine learning was introduced with the arrival of Douglas Pires in 
Cambridge, developing first mCSM for stability [59] followed by several “flavours” 
including mCSM-PPI for impacts on protein-protein interactions, mCSM-NA [60] 
for nucleic acid interactions and mCSM-lig for impacts on small-molecule ligand 
interactions useful for understanding drug resistance [61]. A critical part of using 
machine learning is to have an extensive database of experimentally-defined impacts 
of mutations on stability and interactions, such as Platinum by David Ascher when 
in Cambridge [62], a database of experimentally measured effects of mutations on 
structurally defined protein-ligand complexes that was developed for mCSM-lig. 
These two structural approaches to predicting the impacts of mutations (SDM & 
mCSM) have proved complementary and more reliable than most sequence-only 
Figure 3. 
(A) Protomeric model of PyrG (CTP-Synthase) of M. leprae modelled with a quality of 4.25 (best).  
(B) Homo-8-mer of PyrG of M. leprae modelled with a quality of 4.25 (best).
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Figure 4. 
Indicates the maximum destabilising effect a mutation can induce on the stability of RNA-polymerase 
β-subunit of M. leprae (target for rifampin) measured by mCSM-stability.
methods. They also allow the application of saturation mutagenesis, facilitating  
in silico systematic analysis of mutations [63], an approach now being adopted to 
whole proteomes where every residue in each of the proteins in the proteome is 
mutated to all the other 19 amino acids and the effects of the mutations are measured 
using various methods mentioned above. In structure-guided fragment-based drug 
discovery, this provides comprehensive information on the regions of the protein 
that are less likely to lead to drug resistance and therefore can be probed by elabora-
tion of fragments/small molecules. We performed saturation mutagenesis on the 
drug targets in M. leprae for leprosy and the average or highest impact a mutation 
can induce in each residue position is depicted on the structure (Figure 4).
6.4 Active sites, cavities and fragment hotspot maps
Although comparative modelling of homologues in complex with ligands can 
often give clues about active sites, cofactor binding and substrate or other ligand 
binding sites, this is not always possible. In order to indicate putative binding 
sites in the absence of appropriate experimental data, we have exploited cavity-
defining software such as VolSite [64] for novel binding site description together 
with an alignment and comparison tool (Shaper) [65]. We have used FuzCav, a 
novel alignment-free high-throughput algorithm to compute pairwise similarities 
between protein-ligand binding sites [66] and GHECOM [67], to study the small 
pockets that often characterise protein-protein and protein-peptide interactions.
Further to the identification of cavities and pockets, it is also useful to be able to 
identify hotspots, region(s) of the binding site defined as a major contributor to the 
binding free energy, and often characterised by their ability to bind fragment-sized 
organic molecules in well-defined orientations. The usual understanding is that the 
fragment, with a mixed polar and hydrophobic character, can displace an “unhappy 
water.” We have tried to mimic this in silico by using SuperStar [68] to generate atomic 
interaction propensities on a grid. We then carry out a search with three fragments, 
each having a six-membered carbon ring, but having a donor, acceptor or a non-polar 
substituent. The resulting map is convoluted with an estimate of the depth below the 
surface, which generally appears to correlate with favourable entropic gain on water 
release on binding of a ligand [69]. The hotspot maps, computed in this way and 
13
Computational Deorphaning of Mycobacterium tuberculosis Targets
DOI: http://dx.doi.org/10.5772/intechopen.82374
indicating donor, acceptor and lipophilic interactions correlate well with experimental 
binding sites of fragments that can be elaborated in fragment-based discovery. For the 
ligand bound structures, lower contouring can provide “warm spots” for the binding 
sites, indicating possibilities for elaborating the fragment in the binding pocket.
The models of individual molecules of the modelled proteome can be individually 
decorated with the hotspot maps. They give a good indication of the known func-
tional sites on experimentally defined structures of proteins, often demonstrating 
that a functional site comprises several hotspots involved in binding substrates and 
cofactors. They also provide a good indication of the location of allosteric sites [70].
7. Conclusion
In summary we can move from the study of individual targets to an understanding 
of the majority of targets coded by the genome. Indeed, we can build 3D structures 
for a majority of the genes, so providing a model of the “structural proteome”. 
Hotspots and cavities provide a basis for identification of the ligandability of putative 
binding sites and have been used in our group to predict pharmacophores that can be 
used in docking and virtual screening and so deorphaning of mycobacterial proteins.
To identify druggable proteins from the structural proteome, we have adopted 
a hierarchal selection process wherein chokepoint analysis is initially performed to 
identify metabolic reactions that are critical to cell survival. Gene products identi-
fied in this screen are later subjected to essentiality analysis using either flux balance 
analysis (FBA) based models or by data from the transposon saturation mutagenesis 
experiments in the literature. Genes that are essential are chosen at this stage and 
understanding of the gene expression profiles in different growth conditions is anal-
ysed. Genes whose expression is condition specific are excluded. Later for the selected 
genes, the structural information of the corresponding proteins is analysed in the 
context of prior knowledge and attempts in drug discovery, druggable pockets and 
fragment hotspots maps, small molecule bound states, non-human homologue, non-
homologous to human microbiome, cellular localization and biochemical properties 
of the proteins. Structure-guided virtual screening is performed on the selected drug 
targets with a choice of fragment and compound libraries using CCDC Gold (The 
Cambridge Crystallographic Data Centre) [71]. Best poses with good scores lead the 
experimental process of structure-guided fragment-based drug discovery.
The challenge now is to test the computational methods outlined here for 
identifying ligands and understanding the druggability of the proteome—several 
thousand gene products from the whole genome of Mtb. We can then begin to assess 
the degree to which we can de-orphan the many Mtb proteins that have until now 
not featured as targets in the worldwide efforts to combat the global challenge of TB 
to the health and well-being of human kind.
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